SCHEMBL6806038

SCHEMBL6806038

CCCC(O)N1CCN(C)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.33
GLA P06280 1/20 0.33
IDO1 P14902 1/20 0.33
HTR1A P08908 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
ADRA2A P08913 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
CYP2D6 P10635 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
DRD1 P21728 1/20 0.32
ADRA1D P25100 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
HRH1 P35367 1/20 0.32
OPRM1 P35372 1/20 0.32
DRD3 P35462 1/20 0.32
HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27269583 0.91
SCHEMBL4296118 0.85 GUSB (0.36) KDM4ECYP2D6ALDH1A1CYP1A2
SCHEMBL1404051 0.81 KDM4E (0.35) KDM4EGLAIDO1HTR1ACHRM2
SCHEMBL3248168 0.81 SLC6A3 (0.41) SLC6A3
SCHEMBL8767704 0.81 KDM4E (0.35) KDM4EGLAIDO1HTR1ACHRM2
SCHEMBL22996895 0.80 MC4R (0.34) KDM4EGLAIDO1HTR1ACHRM2
SCHEMBL1650151 0.79 SLC6A3 (0.40) SLC6A3
SCHEMBL23045241 0.77 RAB9A (0.43) SLC6A3
SCHEMBL12706352 0.77
SCHEMBL16972740 0.76 CHRM2 (0.34) KDM4EIDO1HTR1ACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030087981-A1 Floor finish compositions 3M INNOVATIVE PROPERTIES COMPANY 2003-05-08 US claimed
US-6197844-B1 Floor finish compositions 3M INNOVATIVE PROPERTIES COMPANY 2001-03-06 US claimed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
US-6780472-B2 POLYFUNCTIONAL ISOCYANURATE HAVING AT LEAST THREE TERMINAL REACTIVE GROUPS REACTED WITH HYDROXYALKYL ACRYLATE AND TERTIARY AMINE ALCOHOL 3M INNOVATIVE PROPERTIES COMPANY 2004-08-24 US disclosed
WO-2003103652-A1 METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES ELAN PHARMACEUTICALS, INC. (US) 2003-12-18 WO disclosed
US-20030087981-A1 Floor finish compositions 3M INNOVATIVE PROPERTIES COMPANY 2003-05-08 US disclosed
US-6197844-B1 Floor finish compositions 3M INNOVATIVE PROPERTIES COMPANY 2001-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 KDM4E 1299/4885GLA 3946/4885IDO1 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.